In the year 2000, Femarelle^® has started its commercialization stage and consumers around the world have started to enjoy the benefits that it provides. Today Femarelle^® can be found in over 12 countries (also available as Tofupill and Bonfemi).

Femarelle^®'s uniqueness lies in its being a Selective Estrogen Receptor Modulator- a SERM. The selectivity in the estrogen receptor bondage provides both menopausal symptoms relief and bone health, without affecting the sensitive tissues in the breast and uterus.

Thus, Femarelle^® provides a safe and effective solution for the management of menopause.

The scientific activity surrounding Femarelle^® provides published studies in leading scientific journals worldwide, as well as international recognition and acceptance by the medical community both in practice and in leading medical conventions (list of published articles and medical congresses). The research process continues and new studies are constantly being conducted in order to provide comprehensive data proving both the efficacy and safety of use of the product.

Product Information

Name of product: Femarelle^®

Composition: Each capsule contains 322 mg. of DT56a (a unique compound from botanical source) and 108 mg. of flaxseed (adjuvant).

Recommended use: Femarelle^® is intended for women from the time they reach peri-menopause and onward. The therapeutic indication is the relief of menopausal symptoms and bone health.

Recommended intake: 1 capsule twice daily morning and evening; can be taken with or without food.

Femarelle^® is a clinically proven treatment with published studies in leading medical journals.

Published studies have shown:

Efficacy of Femarelle^®

• Femarelle^® combines menopausal symptoms relief and bone health.

• High efficacy:

• Relief is felt within the first week of treatment (avg. 5-7 days).

• Symptoms relief is felt by 3 out of 4 women.

• Hot flushes relief in 76% of the women.

• Joint and muscle pain relief in 70% of the women.

• Headache relief in 68% of the women.

• Femarelle^® increases Bone Mineral Density (BMD).

• Following 12 months of treatment an increase in BMD of 3.6% in the spine and 2.0% in the hip.

• Femarelle^® exhibits unique bone-forming properties by increasing bone formation through osteoblast activity, thus inducing bone rejuvenation.

Safety of Femarelle^®

Femarelle^® was shown to work in a selective manner on the target tissues and thus:

• Femarelle^® does not affect the breast tissue.

• Femarelle^® does not affect the uterus and the endometria.

• Femarelle^® does not affect the Thyroid Stimulating Hormone (TSH).

• Femarelle^® does not affect liver and kidney functions.

• Femarelle^® does not affect the hormonal blood profile.

• Femarelle^® does not induce proliferation of hormone dependant breast cancer cells.

• Furthermore, in the studies and in the data accumulated up to date no serious adverse events have been reported.

Se-cure is highly committed to continue its extensive clinical program and is constantly planning and initiating new studies in order to provide the best and most comprehensive scientific coverage for Femarelle^®.